Active Client · Rare Disease / Dermatology · 2025
Deerfield Group
Equals 5 · NPI-Matched HCP Targeting · Specialty Portfolio
Relationship Since
2025
Direct · Pharma Services Partner
Programs Delivered
2
Danziten + Opzelura · 2025
Therapeutic Areas
2
Rare Disease · Dermatology
NPI Match Rate
90%++
vs. industry avg 40–60%
Executive Snapshot · Deerfield Group
Active Client · May 2026
Updated May 7, 2026
Equals 5 delivers NPI-matched HCP targeting for Deerfield's specialty pharma portfolio — proven delivery across rare disease (Danziten) and dermatology (Opzelura) with physician-level LinkedIn targeting and full funnel analytics.
2
Programs Delivered
2.2M
Verified HCPs
90%++
NPI Match Rate
2
Specialties Served
What EQ5 Does
NPI-matched targeting for rare disease specialists (Danziten/dystonia) and dermatologists (Opzelura/AD + vitiligo). LinkedIn managed service with physician-level sFTP reporting delivered on a weekly cadence. Full funnel analytics from impression through engagement scoring — no black box delivery.
Why It Matters for Deerfield
As a pharma services firm routing programs for portfolio brands, Deerfield needs a media partner that works across specialties without rebuilding the wheel. EQ5's plug-and-play NPI matching works for any indication — rare disease, dermatology, neurology — without new technology setup or renegotiation each time a new brand enters the mix.
Programs
Danziten
Rare Disease · Dystonia (Carbidopa/Levodopa suspension)
Active
Opzelura
Dermatology · Atopic Dermatitis / Vitiligo (Ruxolitinib cream)
Active
Audience
NPI Match Rate
90%++
vs. industry standard 40–60%
EQ5 NPI Datagraph
2.2M
Verified HCPs · specialty coverage
Geographic Scope
National
Dermatology + Rare Disease · US
| Segment | Specialty | Program | Coverage |
|---|---|---|---|
| Segment 1 | Dermatologists | Opzelura (AD & Vitiligo) | Primary |
| Segment 2 | Rare Disease Specialists | Danziten (Dystonia) | Primary |
| Segment 3 | Neurologists | Pipeline / Growth | Expansion |
Channels
LinkedIn
Primary — HCP Social
NPI-matched managed service · Dermatologists + rare disease specialists · Both programs
Programmatic
Add-On — Broader Reach
Display + native · Same NPI cohort · Incremental reach beyond social
sFTP Reporting
Included — All Programs
Weekly physician-level data · Engagement scoring · CRM-ready delivery
Measurement
| Metric | Description | Cadence |
|---|---|---|
| NPI Match Rate | % of submitted HCP list matched & reached across platforms | Per campaign · Verify report |
| Target List Penetration | % of prescribers reached within 60 days of launch | Weekly · sFTP |
| Click-Through Rate | EQ5 benchmark 0.65% · 6.5× industry avg 0.10% | Weekly · per platform |
| Engagement Scoring | Per-HCP scoring: Cold (0–9) → Hot Lead (50+) → Field Ready | Monthly physician report |
| Cross-Channel Frequency | 8–12 verified impressions per HCP per month | Monthly · NPI report |
| Reporting Delivery | Weekly sFTP + monthly physician-level NPI report + quarterly review | Standing cadence |
Timeline
| Program | Deal | Flight | Status |
|---|---|---|---|
| Danziten (Azurity) | eq5-1148 | 2025 Carryover · Jun 2025 | Won |
| Opzelura OnTrac Q4 | eq5-1247 | Q4 2025 · Sep 2025 | Won |
| Neurology / Portfolio Expansion | TBD | 2026 Pipeline | Growth Opportunity |
Client
Deerfield Group
Type
Pharma Services / Investment
Media
Direct (no agency)
Relationship
Since 2025
Therapeutic
Rare Disease · Dermatology · Neurology
NPI Match
90%++
Pipedrive Org
2807
Portfolio Routing Expansion
Neurology and rare disease pipeline — extend the EQ5 routing model to additional Deerfield portfolio brands
Programmatic Add-On
Complement LinkedIn with programmatic display for broader HCP reach within the same NPI cohort at no additional list cost
Account Services Consolidation
Emily Frye handles Opzelura · Mia Lawrence handles Danziten — consolidate to one AS contact to streamline expansion